ABL Bio has received additional milestone payments from Sanofi for its degenerative brain disease treatment candidate ‘ABL301’. Including the upfront payment., ABL Bio will receive a total of KRW 170 billion, which includes the upfront payment.

On 28 February, ABL Bio announced the completion of the manufacturing technology transfer of ABL301 to Sanofi and the receipt of USD 5 million (KRW 7 billion) as a milestone payment.

ABL Bio signed a licensing-out agreement with Genzyme for ABL301, a bispecific antibody candidate for the treatment of Parkinson's disease and other neurodegenerative diseases. Genzyme is a fully-owned subsidiary of Sanofi. The total value of the agree